Nanjing Vcare Debuts at the 93rd API China with One-stop CRO/CDMO Service Platform

2025-11-17

　　The 93rd China International API, Intermediates, Packaging & Machinery Exhibition (API China) was grandly held at Chongqing International Expo Center from November 12 to 14. As a flagship full-industry-chain event for China’s pharmaceutical industry, this exhibition has attracted extensive attention from inside and outside the sector. Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare) made a brilliant appearance at the event, fully demonstrating its R&D and manufacturing strengths covering the entire pharmaceutical industry chain and full life cycle of drugs, and drawing wide attention from numerous domestic and overseas customers.

 

　　Closed-loop Full-industry-chain Capabilities to Accelerate the Process from R&D to Industrialization

 

　　At this exhibition, Nanjing Vcare highlighted its full-layout integration of Chemistry + Pharmacy + Medicine, which garnered great interest among participating enterprises. This closed-loop capability has been well verified by the market. Up to now, Nanjing Vcare has served more than 300 domestic and international pharmaceutical companies, assisted clients in obtaining over 50 marketing approvals for generic drugs and more than 30 clinical trial approvals for innovative drugs, with over 80 projects currently under registration and application.

 

　　Robust Industrial Chain Support to Ensure Safe and Stable Supply Chain

 

　　A solid industrial foundation underpins Nanjing Vcare’s high-quality services. The company owns its subsidiary manufacturing plant — Hubei Tianshu Pharmaceutical Co., Ltd., located in a provincial-level chemical industrial park in Hubei Province, boasting strong supporting production capacity. Nanjing Vcare can steadily supply over 3,000 types of supporting intermediates, impurities and APIs, forming a rich and reliable product portfolio. This vertically integrated industrial chain advantage enables customers to achieve cost control and supply chain security in R&D and production stages, providing strong backend support for their products to enter national centralized procurement and medical insurance negotiations.

 

　　Empowering Customer Development and Creating New Value in Drug R&D

 

　　By participating in this session of API China, Nanjing Vcare not only conducted in-depth exchanges with new and long-term partners, but also showcased its customer-value-centered service philosophy to the whole industry. Driven by technology, the company’s one-stop service platform helps customers and partners optimize R&D strategies, accelerate research progress, control production costs, and ultimately gain an edge in fierce market competition.

 

　　Nanjing Vcare will further deepen the value connotation of its integrated Chemistry + Pharmaceutics + Medicine one-stop service platform, continuously upgrade technological capabilities and manufacturing standards. Joining hands with global partners, the company strives to bring more high-quality drugs to patients at an early date and contribute to the pharmaceutical and healthcare cause in China and across the globe.

 

　　We sincerely invite all industry peers to reunite at the next grand event to discuss development, boost innovation jointly, and create new glories for the pharmaceutical and healthcare industry!

Prev

Nanjing Vcare Shines at the 91st PHARMCHINA: One-stop CRDMO Services Attract Wide Attention

Next

Nanjing Vcare Debuts at 2025 CPHI Frankfurt with Full Pharmaceutical Industry Chain Solutions to Empower Global Pharmaceutical Cooperation